Menu Search
Equities

Otsuka Holdings Co Ltd

4578:TYO

Otsuka Holdings Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)7,922.00
  • Today's Change54.00 / 0.69%
  • Shares traded1.22m
  • 1 Year change+42.23%
  • Beta1.0180
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Otsuka Holdings Co Ltd had net income fall -9.18% from 133.91bn to 121.62bn despite a 16.14% increase in revenues from 1.74tn to 2.02tn.
Gross margin70.66%
Net profit margin6.01%
Operating margin6.20%
Return on assets3.76%
Return on equity5.02%
Return on investment4.70%
More ▼

Cash flow in JPYView more

In 2023, Otsuka Holdings Co Ltd increased its cash reserves by 8.84%, or 41.71bn. The company earned 283.23bn from its operations for a Cash Flow Margin of 14.03%. In addition the company used 190.54bn on investing activities and also paid 60.26bn in financing cash flows.
Cash flow per share435.15
Price/Cash flow per share18.59
Book value per share4,829.27
Tangible book value per share3,260.09
More ▼

Balance sheet in JPYView more

Otsuka Holdings Co Ltd has a Debt to Total Capital ratio of 8.51%, a higher figure than the previous year's 5.24%.
Current ratio2.07
Quick ratio1.66
Total debt/total equity0.0946
Total debt/total capital0.0851
More ▼

Growth rates in JPY

Year on year, growth in dividends per share increased 10.00% while earnings per share excluding extraordinary items fell by -9.19%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)2.22%
Div growth rate (5 year)1.92%
Payout ratio (TTM)51.36%
EPS growth(5 years)8.18
EPS (TTM) vs
TTM 1 year ago		-23.94
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.